

# SUMMARY OF PRODUCT CHARACTERISTICS

## 1-Name of the Medicinal Product :

2      **1.1 Product Name**  
Ultimax Cream

### 2.1 Strength of Active Ingredients

Methyl Salicylate	25.5 % w/w
Eucalyptus Oil	10.0% w/w
Menthol	3.3% w/w

### 1.3 Pharmaceutical Dosage Form

Cream

## 2-Quality and Quantitative Composition :

### 2.1 Qualitative Declaration

Name of Ingredient	%w/w	Reference monograph	Function
Menthol	3.30	USP	Active
Methyl Salicylate	25.50	BP	Active
Eucalyptus Oil	10.00	JP	Active
Carbopol 934	1.00	BP	Viscosity increasing agent
Polysorbate 80	3.10	BP	Emulsifying Agent
Capsicum Oleoresin	0.50	In-house	Irritant
Chlorophyll Oil Soluble	0.20	In-house	Coloring agent
Triethanolamine	2.00	USP	Alkalizing agent
Chlorocresol	0.10	BP	Antimicrobial preservative
Methyl Hydroxybenzoate	0.10	BP	Antimicrobial preservative
Propyl Hydroxybenzoate	0.01	BP	Antimicrobial preservative
Purified Water	54.19	USP	Solvent

\*\* & \*\*\* kindly refer to the calculation of the quantity required

### 2.2 Quantitative Declaration

Refer to Section 2.1 (Qualitative Declaration)

### **3-Pharmaceutical Form :**

Pale green opaque cream

### **4-Clinical Particulars**

#### **4.1 Therapeutic indications**

For temporary relief of pain associated with musculoskeletal soreness and discomfort.

#### **4.2 Posology and method of administration**

For topical use only

Gentle massage on intact skin two to three times a day.

Note : The information given here is limited. For further information consult your doctor or pharmacist.

#### **4.3 Contraindications**

None known

#### **4.4 Special warning and precautions for use**

##### **Warning**

This product is contraindicated in infants under 2 years of age. Caution must be exercised when older children are treated. This product contains methyl salicylate and when applied or rub on to the skin, can be absorbed through the skin into the blood. For patients taking warfarin, excessive application to the skin muscle or joint pains may increase the chances of bleeding.

##### **Precautions**

- It should not be applied to broken or inflamed skin or near the eyes or mucous membranes.
- For external use only.

**4.5 Interaction with other medicinal products and other forms of Interactions**

None known

**4.6 Pregnancy and lactation**

None known

**4.7 Effects on ability to drive and use machine**

Not applicable.

**4.8 Undesirable effects**

Hypersensitivity reactions, urticaria and angioneurotic oedema may occur in susceptible persons.

**4.9 Overdose and special antidotes.**

None known

**5-Pharmacological Properties :**

**5.1 Pharmacodynamic Properties**

Ultimax is used for its local action as a rubefacient-counterirritant analgesic when rubbed on the skin.

**5.2 Pharmacokinetic Properties**

Absorption of methyl salicylate can occur through the skin.

**5.3 Preclinical safety Data**

NOT AVAILABLE

## 6-Pharmaceutical Particulars :

### 6.1 List of excipients

Carbopol 934  
Polysorbate 80  
Capsicum Oleoresin  
Chlorophyll Oil Soluble  
Triethanolamine  
Chlorocresol  
Methyl Hydroxybenzoate  
Propyl Hydroxybenzoate  
Purified Water

### 6.2 Incompatibilities

NOT APPLICABLE

### 6.3 Shelf life

3 years from date of manufacture.

### 6.4 Special precautions for storage

Store below 30°C. Protect from light and freezing.

### 6.5 Nature and contents of container

#### Immediate Container/Packaging

#### Primary Packaging

#### Laminated Tube

Description	:	White laminated tube externally preprinted and cap with 15 mm flower pot design white screw cap
Material of Construction	:	LLDPE 1005 / White Copolymer 605 / Aluminium foil 205 / Copolymer 355 / LLDPE 705

#### Secondary Packaging Components

Outer Container/Packaging  
Type: Ultimex unit box  
Material: Carton

**7-Marketing Authorization Holder :**

Name : HOVID Bhd.  
Address : 121, Jalan Tunku Abdul Rahman,  
(Jalan Kuala Kangsar)  
30010 Ipoh, Perak, Malaysia

**8-Manufacturer Name :**

Name : HOVID Bhd.  
Address : 121, Jalan Tunku Abdul Rahman,  
(Jalan Kuala Kangsar)  
30010 Ipoh, Perak, Malaysia

**9-Date of first authorization/renewal of the authorization :**

July 2019 – July 2024

**10-Date of revision of the text :**

May 2024